ArticleNature reviews bioengineering2024
Bacterial therapies at the interface of synthetic biology and nanomedicine.
Article in Nature reviews bioengineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Microbiome-based therapeutics forGut microbes · 2026Review
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- CD11b agonist GB1275 potentiates oncolytic bacterial therapy against pancreatic cancer in mouse tumor models.Nature communications · 2026Article
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Hydrophilic-Stable Nucleoside-Based Hydrogen-Bonded Organic Frameworks (N-HOF) for Therapeutic Bacterial Hybrid Systems.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Engineered probioticScience advances · 2026Article
- Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine.Journal of advanced research · 2026Review
- Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.Advanced healthcare materials · 2026Review
- RATEX: A Scalable RNA-Based Platform for Logical and Multi-Layered Cellular Programming.Angewandte Chemie (International ed. in English) · 2026Article
- Global Probiotic Markets Meet Synthetic Biology: Translational Challenges andMicroorganisms · 2026Review
- Toward development of soil-derivedBiodesign research · 2026Article
- Bacterial Biohybrids With Dual Magnet and Hypoxia Tropism for Ferroptosis Activation in Deep Tumor Regions.Exploration (Beijing, China) · 2026Article
- Targeting Cancers with Microrobots and Bacteriobots.Molecular biotechnology · 2026Review
- Chitosan-based hydrogel facilitates DC-SIGN-mediated monocyte-to-dendritic cell transformation in vivo for antigen-specific antitumor therapy.Materials today. Bio · 2026Article
- Tumor-specific cytokine therapy mediated by engineered Salmonella with a synthetic protein delivery system.Scientific reports · 2026Article
- Bacteria as living biosensors for DNA.Nature reviews bioengineering · 2026Article
- Rational engineering of combinatorial bacterial therapies for cancer.Genome biology · 2026Review
- Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities.Cell communication and signaling : CCS · 2026Review
- The challenges and strategies for navigatingTheranostics · 2026Review
- Redefining multiple sclerosis therapy through microbial immunomodulation and epigenetic control.Journal of translational autoimmunity · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bacteria are emerging as living drugs to treat a broad range of disease indications. However, the inherent advantages of these replicating and immunostimulatory therapies also carry the potential for toxicity. Advances in synthetic biology and the integration of nanomedicine can address this challenge through the engineering of controllable systems that regulate spatial and temporal activation for improved safety and efficacy. Here, we review recent progress in nanobiotechnology-driven engineering of bacteria-based therapies, highlighting limitations and opportunities that will facilitate clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.